Median time to clinically relevant response as estimated by @ % reduction in clinical signs and symptoms ( CSS ) total score over the entire trial was similar for subjects treated with HC-ac @ % ( @ h ) and for subjects treated with HC-ac @ % ( @ h ) and was considerably and significantly longer for subjects treated with HC-ac @ % ( @ h ) -LSB- p < @ for both dosages -RSB- .